Table 6 Summary of HCV-specific T cell responses obtained with different assays in the three different groups of patients studied
From: Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
| Â | Â | Proliferation Assay | Class II ELISPOT assay | Class I Tetramer Assay | |||
|---|---|---|---|---|---|---|---|
| Â | Number of patients | Time points with at least 1 positive protein | proteins tested positive/time point (mean number) | Time points with at least 1 positive protein | proteins tested positive/time point (mean number) | Time points with at least 1 positive tetramer | tetramers tested positive/time point (n) |
Index patients (Acute resolving hepatitis C) | 7 | 3/19 (16%) | 0.26 | 4/19 (22%) | 0.42 | 5/9 (56%)* | 1.8 |
Chronic hepatitis C | 13 | 2/10 (20%) | 0.20 | 5/20 (25) | 0.30 | - | - |
Anti-HCV+/HCV-RNA- | 9 | 3/9 (33%) | 0.44 | 5/12 (42%) | 0.42 | - | - |